

PROPOSED CLAIMS

United States Application Serial No. 09/910,582
MWE Client/Matter 66654-668 (P-LJ 4857)

Please cancel claim 34.

Please add new claims 35 and 36.

B/ 20. A conjugate, comprising a heart homing peptide linked to a moiety, said heart homing peptide comprising an amino acid sequence selected from the group consisting of

GGGVFWQ (SEQ ID NO: 2);
HGRVRPH (SEQ ID NO: 3);
VVLVTSS (SEQ ID NO: 4);
CLHRGNSC (SEQ ID NO: 9); and
CRSWNKADNRSC (SEQ ID NO: 10), or a functionally equivalent modification peptidomimetic thereof.

21. The conjugate of claim 20, wherein said moiety is selected from the group consisting of a therapeutic agent, a detectable agent and a tag.

22. The conjugate of claim 20, wherein said therapeutic agent is a vascular endothelial growth factor (VEGF).

23. The conjugate of claim 20, wherein said therapeutic agent is a fibroblast growth factor (FGF).

Proposed Claims
U.S. Appl. Ser. No. 09/910,582
Page 2

Cont
B1
24. A method of treating a cardiovascular disease in a subject, comprising administering to a subject in need thereof a conjugate comprising a heart homing peptide linked to a therapeutic agent,

said peptide comprising an amino acid sequence selected from the group consisting of

GGGVFWQ (SEQ ID NO: 2);

HGRVRPH (SEQ ID NO: 3);

VVLVTSS (SEQ ID NO: 4);

CLHRGNSC (SEQ ID NO: 9); and

CRSWNKADNRSC (SEQ ID NO: 10), or a functionally equivalent modification peptidomimetic thereof.

25. The method of claim 24, wherein said cardiovascular disease is atherosclerosis.

26. The method of claim 24, wherein said cardiovascular disease is restenosis.

B2
31. A conjugate, comprising a peptide that selectively homes to ischemic tissue, said peptide linked to a moiety.

Proposed Claims
U.S. Appl. Ser. No. 09/910,582
Page 3

32. The conjugate of claim 31, said peptide comprising an ~~the~~ amino acid sequence selected from the group consisting of
GGGVFWQ (SEQ ID NO: 2);
HGRVRPH (SEQ ID NO: 3);
VVLVTSS (SEQ ID NO: 4);
CLHRGNSC (SEQ ID NO: 9); and
CRSWNKADNRSC (SEQ ID NO: 10), or a functionally equivalent
peptidomimetic thereof.

33. The conjugate of claim 32, wherein said moiety is selected from the group consisting of a therapeutic agent, a detectable agent and a tag.

34. ~~A method of treating ischemic disease in a subject, comprising administering a conjugate comprising an ischemic tissue selective peptide that selectively homes to ischemic tissue, said peptide linked to a moiety.~~

35. The method of claim 24, wherein said cardiovascular disease comprises ischemia.

36. A conjugate, comprising a heart homing peptide that selectively homes to cardiac tissue, comprising an amino acid sequence that has a length of less than 100 amino acids.